<DOC>
	<DOC>NCT00494884</DOC>
	<brief_summary>This study will investigate efficacy and safety of vildagliptin in patients with low baseline levels starting at an HbA1C level of 6.5% to support convenient early intervention with combination therapies. In parallel, morning and evening dosing will be evaluated in this patient population for the first time.</brief_summary>
	<brief_title>Vildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Male, nonfertile female or female of childbearing potential using a medically approved birth control method Patients who have received metformin for at least three months prior to visit 1 and have been on a stable dose for a minimum of 8 weeks prior to visit 1 Agreement to maintain the same dose of metformin throughout the study Age in the range of 1885 years inclusive. HbA1c in the range of 6.5 8.0% (inclusive) at visit 1 Agreement to maintain prior diet and exercise habits during the full course of the study Ability to comply with all study requirements and signed informed consent to participate in the study. Pregnant or lactating female A history of: type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, e.g. Cushing's syndrome and acromegaly. acute metabolic diabetic complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months. Any of the following significant laboratory abnormalities: ALT, AST greater than 2 times the upper limit of the normal range at visit 1. Direct bilirubin greater than the upper limit of the normal range at visit 1. Serum creatinine levels equal to or greater than 1.5 mg/dL (132 umol/L) males, equal to or greater than 1.4 mg/dL (123 umol/L) females, or a history of abnormal creatinine clearance at visit 1. Clinically significant TSH values outside of normal range at visit 1. Clinically significant laboratory abnormalities, confirmed by repeat measurement, other than hyperglycemia, hyperinsulinemia, and glycosuria at visit 1 Treatment with any oral antidiabetic other than metformin within 3 months prior to visit 1 Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>metformin combination</keyword>
</DOC>